Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
View Patent ↗The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
1. A method of indicating the presence of a factor in a biological sample of a cancer patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin comprising:
providing a biological sample;
contacting said biological sample with an antibody or fragment thereof, which is specific for denatured human serum albumin;
contacting said biological sample and said antibody or fragment thereof with denatured human serum albumin; and
detecting the amount of binding of said antibody or fragment thereof to said denatured human serum albumin, wherein an inhibition in binding of said antibody or fragment thereof to said denatured human serum albumin indicates the presence of said factor in said biological sample.
2. The method of claim 1 , wherein said biological sample comprises cancer cells.
3. The method of claim 1 , wherein said biological comprises a tumor extract.
4. The method of claim 3 , wherein said tumor extract is a renal cell carcinoma extract.
5. The method of claim 3 , wherein said tumor extract is a melanoma extract.
6. The method of claim 2 , wherein said biological sample comprises tumor associated inflammatory cells.
7. The method of claim 1 , wherein said biological sample comprises anti-β2-integrin antibodies.
8. The method of claim 7 , wherein said anti-β2-integrin antibodies are selected from the group consisting of CD18, CD11a, CD11b, and CD11c.
9. The method of claim 1 , wherein said biological sample is a human serum.
10. The method of claim 1 , wherein said antibody is monoclonal.
11. The method of claim 1 , wherein said antibody or fragment thereof is immobilized on a solid phase.
12. The method of claim 1 , wherein said denatured human serum albumin is immobilized on a solid phase.
13. A method of indicating the presence of a factor in human serum from a cancer patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin comprising:
providing a sample of human serum;
contacting said sample with an antibody or fragment thereof, which is specific for denatured human serum albumin;
contacting said sample and said antibody or fragment thereof with denatured human serum albumin; and
detecting the amount of binding of said antibody or fragment thereof to said denatured human serum albumin, wherein an inhibition in binding of said antibody or fragment thereof to said denatured human serum albumin indicates the presence of said factor in said sample.
14. The method of claim 13 , wherein said human serum comprises cancer cells.
15. The method of claim 13 , wherein said denatured human serum albumin is immobilized on a solid phase.
16. The method of claim 13 , wherein said antibody is monoclonal.